Obesity Study Upends Heart Risk Assumptions After 40

Across 110 health surveys conducted from 1990 to 2024, researchers found that adults over 40 with obesity often had cholesterol and blood pressure readings that had narrowed toward, disappeared against, or in some cases looked better than those of adults with normal BMI.

That is the uncomfortable center of this obesity study: modern cardiovascular drugs appear to have changed what obesity looks like in the data. Many adults living with obesity now have “indistinguishable” cholesterol and blood pressure levels compared with people at a healthy weight, largely because of statins and antihypertensive drugs, according to Guardian World.

This does not mean obesity is harmless. The researchers and outside experts were explicit about that. It means a simple visual or BMI-based assumption about cardiovascular risk is now less reliable, especially after 40, when preventive treatment becomes more visible in the data.

1990 to 2024: the obesity risk debate got messier because medication changed the numbers

The study, published in The Lancet, examined data on almost 1 million adults aged 20 to 79 from England, Japan, South Korea, Taiwan, Thailand, Finland and the US. The researchers looked at blood pressure, cholesterol levels, BMI scores, and the use of cholesterol-lowering and blood-pressure medicines.

Their central finding was not subtle. Differences in unhealthy cholesterol levels and blood pressure between adults with obesity and those with normal BMI have “narrowed or disappeared” among people aged 40 and over.

“Our study suggests that taking medication to lower blood pressure and cholesterol has helped middle-age and older adults lower their cardiovascular risk to levels that are similar to people with normal BMI [body mass index],” said Prof Majid Ezzati of Imperial College London.

XOOMAR analysis: the deeper story is not that weight stopped mattering. It is that treatment changed the measurement. A person with obesity who is treated aggressively for cholesterol and blood pressure may show better readings than a normal-BMI person who is untreated. That complicates lazy assumptions about health based on body size alone.

After 40, statins and blood-pressure drugs narrowed the measurable health gap

The age split matters. The convergence appeared especially among people older than 40, while adults under 40 with obesity still had higher levels of bad cholesterol and higher blood pressure than their normal-BMI counterparts.

That makes the study less a broad defense of obesity and more a report card on preventive cardiology. Statins and antihypertensives are doing exactly what they are supposed to do: lowering measurable cardiovascular risk factors in people more likely to be prescribed them.

The researchers wrote that in England, the US, Thailand, South Korea, and Japan, older people with obesity often became “indistinguishable from, or better off than” those with normal BMI in terms of non-HDL cholesterol and systolic blood pressure.

That phrase, “better off,” needs care. It refers to specific measured cardiometabolic traits. It does not cover total health. It does not erase obesity-linked risks outside cholesterol and blood pressure, including those named by the British Heart Foundation: diabetes, kidney disease, and some cancers.

The actual measures: BMI, non-HDL cholesterol, systolic blood pressure, and treatment use

The strongest part of this obesity study is its scale and its focus on real-world treatment. The researchers used survey data collected across more than three decades and examined medication use alongside BMI and risk markers.

The Guardian report names the core markers as BMI, blood pressure, cholesterol levels, non-HDL cholesterol, and systolic blood pressure. It does not provide exact numeric cholesterol or blood-pressure readings in the supplied material, so the finding should be read as a direction-of-change result rather than a bedside threshold guide.

A treated reading is still a real reading. If medication brings systolic blood pressure or non-HDL cholesterol down, that is a health gain. But XOOMAR analysis: treated risk is not identical to never-developed risk. A snapshot of controlled numbers cannot, by itself, answer how long someone had elevated pressure or cholesterol before treatment, or what other obesity-related pathways remain active.

That distinction is the useful takeaway. The data show control. They do not prove biological equivalence across all outcomes.

The public-health win is real, but it is not a free pass for obesity

Prof Bryan Williams, chief scientific and medical officer at the British Heart Foundation, framed the finding as a success for modern treatment.

“This study highlights a powerful public health success story – it shows just how effective modern treatments for blood pressure and cholesterol have become.”

He then drew the line the headline risks blurring.

“But we must not lose sight of the bigger picture. These medications are needed because of the adverse effects of obesity on cardiovascular disease risk. Moreover, obesity still affects the body in many other ways and increases the risk of other health problems, including diabetes, kidney disease and some cancers.”

That is the balance. The medicines work. The underlying condition still matters.

This is also where public messaging often fails. If obesity is treated only as personal failure, the success of medication gets ignored. If normalized blood pressure and cholesterol are treated as proof that obesity no longer matters, other risks get ignored. The study points to a more precise middle ground: risk can be reduced without being eliminated.

Weight-loss drugs make the timing more consequential

The researchers said the findings help “give a picture of the cardiovascular health” of people likely to be prescribed weight-loss medications, which have rapidly increased in popularity. Ezzati also said the results could help healthcare systems understand how blood-pressure and cholesterol treatments benefit the population alongside weight-loss medications.

That does not establish how weight-loss drugs should be prescribed. The supplied material does not provide eligibility rules, cost data, insurer responses, or drugmaker statements. It does, however, show why the conversation is getting more complicated.

If a patient over 40 with obesity has controlled blood pressure and cholesterol because of medication, the clinical conversation cannot stop at BMI. It has to separate what is controlled from what remains unresolved.

For readers who follow XOOMAR’s wider evidence-driven coverage, the same discipline applies across very different stories: stay inside what the data show. That is true in public-health reporting such as 400 Cases Send CDC Chasing 18-State Cyclospora Trail, and in policy analysis such as Trump Turns USMCA Renewal Into a Trade Pressure Trap, where overreading limited facts can distort the real stakes.

For over-40s, good numbers are good news, not the whole diagnosis

For patients, the practical message is direct. If prescribed drugs have brought cholesterol and blood pressure under control, that is meaningful. It likely reflects successful risk-factor management, and it should not be dismissed.

But nobody should read this obesity study as permission to stop medication, skip checkups, or assume BMI tells the whole story. The authors themselves found that under-40s with obesity still had higher bad cholesterol and higher blood pressure. Gregg also warned that the findings do not mean obesity stops increasing the risk of other outcomes.

A better clinical question is: which risks are controlled, which are not, and which interventions change long-term outcomes? That can include medication adherence, screening, weight management, and monitoring for conditions the source specifically names, including diabetes, kidney disease, and some cancers.

The next test is whether risk models catch up with treated reality

The next research fight will not be over whether obesity matters. The evidence here does not support that escape hatch. The sharper question is how health systems should interpret obesity when major cardiovascular markers are already being treated successfully.

Evidence that would strengthen the study’s thesis would include continued convergence in treated older adults across future surveys, especially in non-HDL cholesterol and systolic blood pressure. Evidence that would weaken it would show that controlled markers fail to translate into better long-term outcomes, or that other obesity-related risks dominate despite improved cardiovascular readings.

For now, the cleanest read is this: the study does not let obesity off the hook. It shows that medicine has already changed what obesity looks like in the numbers.

Key Takeaways

• The findings suggest statins and antihypertensive drugs are reshaping how obesity-related cardiovascular risk appears in health data.
• BMI alone may be a less reliable shortcut for assessing heart risk in adults over 40.
• The study does not show obesity is harmless, but it complicates assumptions based only on weight.